Skip to main content
SpringerLink
Log in

Chronic Graft-Versus-Host Disease

Pathogenesis and Clinical Management

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Chronic graft-versus-host disease (cGVHD) is the most common and severe complication among patients surviving >100 days after allogeneic transplantation. It starts with the expansion of donor T cells in response to alloantigens or autoantigens that are unchecked by normal thymic or peripheral mechanisms of deletion. The T cells induce damage to target organs either directly through cytolytic attack, inflammatory cytokines and fibrosis, or by promoting B cell activation and production of autoantibodies.

HLA disparity, donor and patient age and sex, source of progenitor cells, graft composition and previous acute GVHD are the main factors that predict the risk of developing cGVHD. Once the diagnosis has been established, patients needing treatment (extensive cGVHD) must be identified. Poor prognostic factors such as extensive skin involvement, thrombocytopenia and progressive-type onset of cGVHD must be considered in order to define the immunosuppressive treatment requirements.

Prednisone, together with a calcineurin inhibitor such as ciclosporin or tacrolimus, can be considered the standard regimen as primary treatment for cGVHD. Using that approach, among high-risk patients (identified as those with extensive cGVHD plus thrombocytopenia) 3-year survival reached 52%. Concerning salvage regimens, to date there is no clear standard regimen for cGVHD treatment, the best choice being to enter the patient into a clinical trial. Immunosuppressive drugs that inhibit T cell activation, proliferation or survival, such as mycophenolate mofetil, the anti-interleukin-2α receptor antagonist daclizumab, sirolimus (rapamycin), extracorporeal photopheresis and pentostatin (deoxycoformycin), among other agents, have been used with a very wide range of complete responses ranging from 5% to 50%. In addition, anti-cytokine or B cell inhibitors such as etanercept or rituximab have also been evaluated.

The severe immunosuppression induced by those drugs increases the risk of infectious complications and may have a deleterious effect on the graft versus tumour effect after transplant so that newer strategies based on the selective depletion of alloreactive T cells and induction of more specific immunotolerance against host tissues are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III

Similar content being viewed by others

References

  1. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogenic blood stem cell transplantation. Blood 1999; 94: 1465–70

    PubMed  CAS  Google Scholar 

  2. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18(3): 537–46

    PubMed  CAS  Google Scholar 

  3. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344(3): 175–81

    Article  PubMed  CAS  Google Scholar 

  4. Mohty M, Kuentz M, Michallet M, et al. cGVHD after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100(9): 3128–34

    Article  PubMed  CAS  Google Scholar 

  5. Powels R, Metha J, Kulkarni S, et al. Allogenic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355(9211): 1231–7

    Article  Google Scholar 

  6. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of cronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100(2): 415–9

    Article  PubMed  CAS  Google Scholar 

  7. Díez-Campelo M, Pérez-Simón JA, González-Porras JR, et al. Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic vs autologous transplantation: results of a prospective study. Bone Marrow Transplant 2004; 34(8): 729–38

    Article  PubMed  Google Scholar 

  8. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft versus host disease. Int J Hematol 2003; 78: 181–7

    Article  PubMed  CAS  Google Scholar 

  9. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft versus host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754–9

    PubMed  CAS  Google Scholar 

  10. Reddy P. Pathophysiology of acute graft versus host disease. Hematol Oncol 2003; 21: 149–61

    Article  PubMed  Google Scholar 

  11. Goker H, Haznedaroglu I, Chao N. Acute graft versus host disease: pathobiology and management. Exp Hematol 2001; 29: 259–77

    Article  PubMed  CAS  Google Scholar 

  12. Couriel D, Caldera H, Champlin R, et al. Acute graft versus host disease: pathophysiology, clinical manifestations and management. Cancer 2004; 101: 1936–46

    Article  PubMed  Google Scholar 

  13. Hakim F, Mackall C. The immune system: effector and target of graft versus host disease. In: Ferrara J, Deeg J, Burakoff S, editors. Graft versus host disease. New York: Marcel Dekker Inc., 1997: 275–290

    Google Scholar 

  14. Lee S. New approaches for preventing and treating chronic graft versus host disease. Blood 2005; 105: 4200–6

    Article  PubMed  CAS  Google Scholar 

  15. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft versus host disease syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–17

    Article  PubMed  CAS  Google Scholar 

  16. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft versus host disease. Bone Marrow Transplant 1989; 4: 247–54

    PubMed  CAS  Google Scholar 

  17. Akpek G, Zahurak M, Piantadosi S, et al. Development of a prognostic model for grading chronic graft versus host disease. Blood 2001; 97: 1219–26

    Article  PubMed  CAS  Google Scholar 

  18. Martino R, Caballero D, Pérez-Simón JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndroms. Blood 2002; 100(6): 2243–5

    Article  PubMed  CAS  Google Scholar 

  19. Pérez-Simón JA, Martino R, Alegre A, et al. Chronic but not acute graft versus host disease improves outcome in multiple myeloma patients after nonmyeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104–8

    Article  PubMed  Google Scholar 

  20. Pérez-Simón J, Díez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102(3): 1108–13

    Article  PubMed  CAS  Google Scholar 

  21. Pérez-Simón JA, Caballero D, Lopez-Pérez R, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16(8): 1423–31

    Article  PubMed  Google Scholar 

  22. Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukaemia. Blood 2002; 100: 3877–86

    Article  PubMed  CAS  Google Scholar 

  23. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneicmarrow grafts. N Engl J Med 1979; 300: 1068–73

    Article  PubMed  CAS  Google Scholar 

  24. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–33

    Article  PubMed  CAS  Google Scholar 

  25. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–8

    PubMed  CAS  Google Scholar 

  26. Ringden O, Hermans J, Labopin M, et al. A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versushost disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996; 24: 71–9

    Article  PubMed  CAS  Google Scholar 

  27. Atkinson K, Incefy GS, Storb R, et al. Low serum thymic hormone levels in patients with chronic graft versus host disease. Blood 1982; 59: 1073–7

    PubMed  CAS  Google Scholar 

  28. Vogelsang G. How I treat chronic graft versus host disease. Blood 2001; 97: 1196–201

    Article  PubMed  CAS  Google Scholar 

  29. Sullivan K. Graft versus host disease. In: Blume K, Forman S, Appelbaum F, editors. Thoma’s hematopoietic cell transplantation. Maiden (MA): Blackwell Science Inc., 2004; 50: 635–64

    Google Scholar 

  30. Morris SC, Cheek RL, Cohen PL, et al. Allotype-specific immunoregulation of autoantibody production by host B cells in chronic graft versus host disease. J Immunol 1990; 144: 916–22

    PubMed  CAS  Google Scholar 

  31. Saitoh T, Fujiwara M, Asakura H. L3T4+ T cells induce hepatic lesions resembling primary biliary cirrhosis in mice with graft versus host reaction due to major histocompatibility complex class II disparity. Clin Immunol Immunopathol 1991; 59: 449–61

    Article  PubMed  CAS  Google Scholar 

  32. Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant 1990; 6: 93–6

    PubMed  CAS  Google Scholar 

  33. Wesierska-Gadek J, Penner E, Hitchman E, et al. Nucleolar proteins B23 and C23 as target antigens in chronic graft versus host disease. Blood 1992; 79: 1081–6

    PubMed  CAS  Google Scholar 

  34. Garsili CG, Pennline KJ, Smith SR, et al. Cytokine gene expression in mice undergoing chronic graft versus host disease. Mol Immunol 1993; 30: 669–77

    Article  Google Scholar 

  35. De Wit D, van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft versus host reaction. J Immunol 1993; 150: 361–6

    PubMed  Google Scholar 

  36. Jordan W, Brookes P, Szydlo R, et al. IL-13 production by donor T cells is prognostic of acute graft versus host disease following unrelated donor stem cell transplantation. Blood 2004; 103: 717–24

    Article  PubMed  CAS  Google Scholar 

  37. Rus V, Svetic A, Nguyen P, et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 1995; 155(5): 2396–406

    CAS  Google Scholar 

  38. Sanchez-Guijo FM, Sánchez-Abarca LI, Bueno C, et al. Longterm immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors. Biol Blood Marrow Transplant 2005; 11(5): 354–61

    Article  PubMed  Google Scholar 

  39. Korholz D, Kunst D, Hempel L, et al. Decreased IL 10 and increased interferon gamma production in patients with chronic graft versus host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 691–5

    Article  PubMed  CAS  Google Scholar 

  40. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002; 99: 351–8

    Article  PubMed  CAS  Google Scholar 

  41. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–5

    Article  PubMed  CAS  Google Scholar 

  42. Shlomchik WC, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen presenting cells. Science 1999; 285: 412–5

    Article  PubMed  CAS  Google Scholar 

  43. Anderson B, McNiff J, Jain D, et al. Distinct roles for donor and host derived antigen presenting cells and costimulaory molecules in murine chronic graft versus host disease: requirements depend on target organ. Blood 2005; 105: 2227–34

    Article  PubMed  CAS  Google Scholar 

  44. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graftversus-host disease. Blood 2005; 106(8): 2903–11

    Article  PubMed  CAS  Google Scholar 

  45. Clark F, Gregg R, Piper K, et al. Chronic graft versus host disease is associated with increased numbers of peripheral blood CD4+CD25 high regulatory T cells. Blood 2004; 103: 2410–6

    Article  PubMed  CAS  Google Scholar 

  46. Sullivan K, Agura E, Anasetti C. Chronic graft versus host disease in other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–9

    PubMed  CAS  Google Scholar 

  47. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004; 104: 1923–30

    Article  PubMed  CAS  Google Scholar 

  48. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematpoietic cell transplantation. Blood 2003; 9: 610–5

    Google Scholar 

  49. Hurley CK, Baxter LA, Logan B, et al. National marrow donor program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 1999; 5: 347–56

    Article  Google Scholar 

  50. Kollman C, Howe C, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043–51

    Article  PubMed  CAS  Google Scholar 

  51. Santo Tomas LH, Loberiza FR, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128(1): 153–61

    Article  PubMed  Google Scholar 

  52. Miklos DB, Kim HT, Guo L, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graftversus-host disease and disease remission. Blood 2005; 105(7): 2973–8

    Article  PubMed  CAS  Google Scholar 

  53. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18(3): 537–46

    PubMed  CAS  Google Scholar 

  54. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344(3): 175–81

    Article  PubMed  CAS  Google Scholar 

  55. Mohty M, Kuentz M, Michallet M, et al. Chronic graft-versushost disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002; 100(9): 3128–34

    Article  PubMed  CAS  Google Scholar 

  56. Powels R, Metha J, Kulkarni S, et al. Allogenic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355(9211): 1231–7

    Article  Google Scholar 

  57. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft versus host disease after allogeneic peripheral blood stem cell transplantation: a metaanalysis. J Clin Oncol 2001; 19: 3685–91

    PubMed  CAS  Google Scholar 

  58. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukaemia. Blood 2002; 100: 761–7

    Article  PubMed  CAS  Google Scholar 

  59. Couban S, Simpson D, Barnett M, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525–31

    Article  PubMed  CAS  Google Scholar 

  60. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100(2): 415–9

    Article  PubMed  CAS  Google Scholar 

  61. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–75

    Article  PubMed  CAS  Google Scholar 

  62. Vanderson R, Lobopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukaemia. N Engl J Med 2004; 351: 2276–85

    Article  Google Scholar 

  63. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymovyte globulin for graft versus host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from GITMO. Blood 2001; 98: 2942–7

    Article  PubMed  CAS  Google Scholar 

  64. Urbano-Ispizua A, Rozman C, Martinez C, et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997; 89: 3967–73

    PubMed  CAS  Google Scholar 

  65. Pérez-Simón JA, Kottaridis P, Martino R, et al. Non-myeloablative transplants with or without CAMPATH-1H: comparison between two prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100(9): 3121–7

    Article  PubMed  CAS  Google Scholar 

  66. Pavletic S, Carter S, Kernan N, et al. Influence of T cell depletion on chronic graft versus host disease: results of a multicenter randomised trial in unrelated donor transplantation. Blood 2005; 106(9): 3308–13

    Article  PubMed  CAS  Google Scholar 

  67. Zaucha JM, Gooley T, Bensinger WI, et al. CD 34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engrafment kinetics and development of extensive cronic graft-versus-host disease after human leucocyte antigen-identical sibling transplantation. Blood 2001; 98(12): 3221–7

    Article  PubMed  CAS  Google Scholar 

  68. Carvallo C, Geller N, Kurlander R, et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 2004; 103: 1560–3

    Article  PubMed  CAS  Google Scholar 

  69. Chen B, Cui X, Sempowski G, et al. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004; 103: 4344–52

    Article  PubMed  CAS  Google Scholar 

  70. Baron F, Marin MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005; 19(5): 822–88

    Article  PubMed  CAS  Google Scholar 

  71. Bittencourt H, Rocha V, Chevret S. Association of CD 34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99(8): 2726–33

    Article  PubMed  CAS  Google Scholar 

  72. Dominietto A, Lamparelli T, Raiola AM, et al. Transplantrelated mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogenic marrow transplantation. Blood 2002; 100(12): 3930–94

    Article  PubMed  CAS  Google Scholar 

  73. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute grant versus host disease. Biol Blood Marrow Transplant 1999; 5: 347–56

    Article  PubMed  CAS  Google Scholar 

  74. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–62

    Article  PubMed  CAS  Google Scholar 

  75. Pérez-Simón JA, Díez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft versus host disease after allogeneic transplantation. Br J Haematol 2005; 130(3): 394–403

    Article  PubMed  Google Scholar 

  76. Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graftversus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–85

    Article  PubMed  Google Scholar 

  77. Ochs LA, Miller WJ, Filipovich AH, et al. Predictive factors for chronic graft versus host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13: 455–60

    PubMed  CAS  Google Scholar 

  78. Lee S, Klein J, Barret J, et al. Severity of chronic graft versus host disease: association with treatment related mortality and relapse. Blood 2002; 100: 406–14

    Article  PubMed  CAS  Google Scholar 

  79. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–55

    Article  Google Scholar 

  80. Pavletic S, Smith L, Bishop M, et al. Prognostic factors of chronic graft versus host disease after allogeneic blood stem cell transplantation. Am J Hematol 2005; 78: 265–74

    Article  PubMed  Google Scholar 

  81. Akpek G, Lee SL, Flowers ME, et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102: 802–9

    Article  PubMed  CAS  Google Scholar 

  82. Stewart B, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft versus host disease. Blood 2004; 104: 3501–6

    Article  PubMed  CAS  Google Scholar 

  83. Shulman HM, Kleiner D, Lee SJ, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology workng group report. Biol Blood Marrow Transplant 2006; 12: 31–47

    Article  Google Scholar 

  84. Syrjala KL, Chapko MK, Vitaliano PP, et al. Recovery alter allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11: 319–27

    PubMed  CAS  Google Scholar 

  85. Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous leucemia in prolonged first complete remission alter bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of EORTC-GIMEMA AML 84 trial. Bone Marrow Transplant 1997; 20: 307–15

    Article  PubMed  CAS  Google Scholar 

  86. Andrykowski MA, Henslee PJ, Farral MG. Physical and psychosocial functioning of adult survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 75–81

    PubMed  CAS  Google Scholar 

  87. Belec RH. Quality of life: perceptions of long-term survivors of bone marrow transplantation. Oncol Nurs Forum 1992; 19: 31–7

    PubMed  CAS  Google Scholar 

  88. Jenkins PL, Linington A, Whittaker JA. A retrospective study of psychosocial morbidity in bone marrow transplantation recipients. Psychosomatics 1991; 32: 65–71

    Article  PubMed  CAS  Google Scholar 

  89. Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89: 2602–9

    PubMed  CAS  Google Scholar 

  90. Radich J, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632–8

    PubMed  CAS  Google Scholar 

  91. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for the treatment of chronic graft versus host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–54

    PubMed  CAS  Google Scholar 

  92. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft versus host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1988; 57: 267–76

    Google Scholar 

  93. Koc S, Leisenring W, Flowers M, et al. Therapy for chronic graft versus host disease: a randomised trial comparing cyclosporine and prednisone versus prednisone alone. Blood 2002; 100: 48–51

    Article  PubMed  CAS  Google Scholar 

  94. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine and prednisone as initial therapy for chronic graft versus host disease. Biol Blood Marrow Transplant 2001; 7: 265–73

    Article  PubMed  CAS  Google Scholar 

  95. Koc S, Leisenring W, Flowers M, et al. Thalidomide for the treatment of patients with chronic graft versus host disease. Blood 2000; 96: 3995–6

    PubMed  CAS  Google Scholar 

  96. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 307–13

    Article  PubMed  CAS  Google Scholar 

  97. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002; 5: 287–95

    Article  Google Scholar 

  98. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after nonmyeloablative allogeneic transplantation using a daclizumabbased strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777–86

    Article  PubMed  CAS  Google Scholar 

  99. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–9

    PubMed  CAS  Google Scholar 

  100. Blaise D, Olive D, Michallet M, et al. Impairment of leukaemiafree survival by addition of interleukin-2-receptor antibody to standard graft versus-host prophylaxis. Lancet 1995; 345: 1144–6

    Article  PubMed  CAS  Google Scholar 

  101. Couriel DR, Saliba R, Escalon P, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft versus host disease. Br J Haematol 2005; 130: 409–17

    Article  PubMed  CAS  Google Scholar 

  102. Johnston L, Brown J, Shizuru J, et al. Rapamycin (sirolimus) for the treatment of chronic graft versus host disease. Biol Blood Marrow Transplant 2005; 11: 47–55

    Article  PubMed  CAS  Google Scholar 

  103. Goldberg J, Jacobson D, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003; 25(7): 584–8

    Article  PubMed  Google Scholar 

  104. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003; 102: 1217–23

    Article  PubMed  CAS  Google Scholar 

  105. Couriel D, Hosing C, Saliva R, et al. Extracorporeal photopheresis for acute and chronic graft versus host disease: does it work? Biol Blood Marrow Transplant 2006; 12: 37–40

    Article  PubMed  Google Scholar 

  106. Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versushost disease (GVHD). Bone Marrow Transplant 1999; 23: 881–7

    Article  PubMed  CAS  Google Scholar 

  107. Besnier DP, Chabannes D, Mahe B, et al. Treatment of graftversus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997; 64: 49–54

    Article  PubMed  CAS  Google Scholar 

  108. Rossetti F, Zulian F, Dall’Amico R, et al. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation 1995; 59: 149–51

    Article  PubMed  CAS  Google Scholar 

  109. Alcindor T, Gorgun G, Miller BK. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001; 98: 1622–5

    Article  PubMed  CAS  Google Scholar 

  110. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133: 275–9

    PubMed  CAS  Google Scholar 

  111. Ratanetharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505–11

    Article  CAS  Google Scholar 

  112. Canninga-Van Dijk MR, Van Der Staaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy refractory chronic graft-versus-host disease. Blood 2004; 104: 2603–6

    Article  PubMed  CAS  Google Scholar 

  113. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665–7

    Article  PubMed  CAS  Google Scholar 

  114. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977–83

    Article  PubMed  CAS  Google Scholar 

  115. Fried RH, Murakami CS, Fisher LD, et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116: 624–9

    PubMed  CAS  Google Scholar 

  116. Chiba T, Yokosuka O, Kanda T, et al. Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid. Liver 2002; 22: 514–7

    Article  PubMed  Google Scholar 

  117. Iyer R, Hahn T, Roy H, et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 587–92

    Article  PubMed  CAS  Google Scholar 

  118. Margolis J, Vogelsang G. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. Semin Oncol 2000; 27: 72–7

    PubMed  CAS  Google Scholar 

  119. Bolaños-Meade J, Jacobson D, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23: 2661–8

    Article  PubMed  CAS  Google Scholar 

  120. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graftversus-host disease. Br J Haematol 2005; 130: 271–5

    Article  PubMed  CAS  Google Scholar 

  121. Wada H, Mori A, Okada M, et al. Treatment of intestinal graft versus host disease using betamethasone enemas. Transplantation 2001; 72: 1451–3

    Article  PubMed  CAS  Google Scholar 

  122. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001; 137(9): 1202–6

    PubMed  CAS  Google Scholar 

  123. Eckard A, Starke O, Stadler M, et al. Severe oral chronic graftversus-host disease following allogeneic bone marrow tans-plantation: highly effective treatment with topical tacrolimus. Oral Oncol 2004; 40(8): 811–4

    Article  Google Scholar 

  124. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12: 138–51

    Article  PubMed  Google Scholar 

  125. Solomon S, Mielke S, Savani B, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123–9

    Article  PubMed  CAS  Google Scholar 

  126. Martin P, Pei J, Gooley T, et al. Evaluation of a CD25 specific immunotoxin for prevention of graft versus host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 2004; 10: 552–60

    Article  PubMed  CAS  Google Scholar 

  127. Blanco B, Pérez-Simón J, Sánchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2005 Nov 10, [Epub ahead of print]

  128. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–6

    PubMed  CAS  Google Scholar 

  129. Sakaguchi S. Naturally arising CD4 regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531–62

    Article  PubMed  CAS  Google Scholar 

  130. Suciu-Foca N, Manavalan JS, Cortesini R. Generation and function of antigen-specific supresor and regulatory T cells. Transpl Immunol 2003; 11: 235–44

    Article  PubMed  CAS  Google Scholar 

  131. Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol 2003; 11: 267–76

    Article  PubMed  CAS  Google Scholar 

  132. Taylor P, Lees C, Blazar B. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft versus host disease lethality. Blood 2002; 99(10): 3493–9

    Article  PubMed  CAS  Google Scholar 

  133. Godfrey W, Ge Y, Spoden D, et al. In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. Blood 2004; 104(2): 453–61

    Article  PubMed  CAS  Google Scholar 

  134. Battaglia M, Stabilini A, Roncarolo M. Rapamycin selectively expands CD4+CD25+FOXP3+ regulatory T cells. Blood 2005; 105(12): 4743–8

    Article  PubMed  CAS  Google Scholar 

  135. Mahnke K, Qian Y, Knop J, et al. Induction of CD4+CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003; 101(12): 4862–9

    Article  PubMed  CAS  Google Scholar 

  136. Steinman R, Hawiger D, Nussenzweig M. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685–711

    Article  PubMed  CAS  Google Scholar 

  137. Fresnay E, Garnache-Ottou F, Plumasm J, et al. Can tolerogenic dendritic cells help to modulate allo-immune responses in the setting of hematopoietic cell transplantation? Transpl Immunol 2003; 11: 259–66

    Article  PubMed  CAS  Google Scholar 

  138. Penna G, Adorini L. 1,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405–11

    PubMed  CAS  Google Scholar 

  139. Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits Il-4 induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457–63

    Article  PubMed  CAS  Google Scholar 

  140. Abe M, Thomson AW. Influence of immunosuppressive drugs on dendritis cells. Transpl Immunol 2003; 11: 357–65

    Article  PubMed  CAS  Google Scholar 

  141. Beith S, Borovsky Z, Mevorach D, et al. Human mesechymal stem cells alter antigen-presenting maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214–9

    Article  CAS  Google Scholar 

  142. Jiang X-X, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120–6

    Article  PubMed  CAS  Google Scholar 

  143. Rasmusson I, Ringdén O, Sundberg B, et al. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33–41

    Article  PubMed  CAS  Google Scholar 

  144. Aggarwal S, Pittenger M. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105(4): 1815–22

    Article  PubMed  CAS  Google Scholar 

  145. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigenspecific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516–25

    PubMed  CAS  Google Scholar 

  146. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft versus host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–41

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partially supported by a grant from the Junta de Castilla y León (SACYL 2004). The authors have no potential conflicts of interest directly related to the contents of this article.

Author information

Authors and Affiliations

  1. Servicio de Hematología, Hospital Clínico Universitario Paseo de San Vicente s/n, 37007, Salamanca, Spain

    José A Peréz-Simón, Ignacio Sánchez-Abarca, María Díez-Campelo, Dolores Caballero & Jesús San Miguel

Authors
  1. José A Peréz-Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ignacio Sánchez-Abarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María Díez-Campelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dolores Caballero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jesús San Miguel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José A Peréz-Simón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peréz-Simón, J.A., Sánchez-Abarca, I., Díez-Campelo, M. et al. Chronic Graft-Versus-Host Disease. Drugs 66, 1041–1057 (2006). https://doi.org/10.2165/00003495-200666080-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666080-00002

Keywords

Search

Navigation